Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Jasper Therapeutics Inc

Healthcare US JSPR

1.37USD
0.06(4.58%)

Last update at 2026-03-10T20:00:00Z

Day Range

1.311.41
LowHigh

52 Week Range

4.0031.01
LowHigh

Fundamentals

  • Previous Close 1.31
  • Market Cap361.75M
  • Volume446421
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-67.75300M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-61.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -37.68500M -30.63700M -31.66900M -
Minority interest - - - -
Net income -24.17400M -23.98400M -31.66900M -
Selling general administrative 16.57M 11.41M 4.80M -
Selling and marketing expenses - - - -
Gross profit 13.51M 6.20M - -
Reconciled depreciation 0.97M 0.38M 0.00000M -
Ebit -51.19600M -36.83300M -20.68300M -4.71000M
Ebitda -64.12100M -43.10900M -9.80800M -
Depreciation and amortization -12.92500M -6.27600M 10.88M -
Non operating income net other - - -5.50685M -
Operating income -51.19600M -36.83300M -20.68300M -
Other operating expenses 51.20M 36.83M 20.68M -
Interest expense 13.51M 6.20M 10.99M 0.00000M
Tax provision - - - -
Interest income - - - -
Net interest income - - - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -13.51100M -6.65300M -0.03845M -
Total revenue 13.51M 6.20M 0.00000M -
Total operating expenses 51.20M 36.83M 20.68M -
Cost of revenue - - - -
Total other income expense net 13.51M 6.20M -10.98600M -
Discontinued operations - - - -
Net income from continuing ops -51.19600M -36.83300M -6.48070M -
Net income applicable to common shares -37.68500M -30.63700M -6.48070M -4.98700M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 95.38M 48.36M 93.65M 23.36M 100.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.80M 2.82M 3.13M 0.15M 0.33M
Total liab 14.68M 12.37M 24.14M 58.49M 3.61M
Total stockholder equity 78.44M 35.99M 69.52M -35.13000M 5.00M
Deferred long term liab - - - - -
Other current liab 7.25M 4.43M 0.79M 2.60M -
Common stock 0.00100M 0.00400M 0.00400M 0.00100M 0.00036M
Capital stock 0.00100M 0.00400M 0.00400M 0.00100M -
Retained earnings -169.60000M -105.13500M -67.45000M -36.81300M 0.00204M
Other liab - 2.52M 13.74M 9.01M 4.12M
Good will - - - - -
Other assets 0.00000M 1.18M 0.99M 0.64M 0.05M
Cash 86.89M 38.25M 84.70M 19.84M 1.21M
Cash and equivalents - - - - -
Total current liabilities 12.37M 7.07M 8.02M 4.01M 0.11M
Current deferred revenue - - 2.81M - -
Net debt -84.10100M -34.59900M -81.81600M -18.21400M -
Short term debt 0.97M 0.86M 0.51M - -
Short long term debt - - - - -
Short long term debt total 2.79M 3.65M 2.88M 1.62M -
Other stockholder equity 248.04M 92.76M 136.96M 1.68M -
Property plant equipment - 3.57M 4.83M 2.03M -
Total current assets 88.94M 41.73M 87.83M 20.68M 100.15M
Long term investments - - - 100.34M 100.15M
Net tangible assets - 35.99M 69.52M 84.36M 98.08M
Short term investments - - - - 100.15M
Net receivables 0.25M 0.66M 0.70M 0.60M -
Long term debt - - - 13.13M -
Inventory - - 2.41M 0.10M -
Accounts payable 4.15M 1.77M 3.92M 1.42M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -93.65400M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00400M 0.00400M 0.00046M 0.00036M
Preferred stock total equity - - - - -
Retained earnings total equity - -105.13500M -67.45000M -7.07708M 0.00204M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.34M 1.18M 0.99M 0.64M -
Deferred long term asset charges - - - - -
Non current assets total 6.44M 6.63M 5.82M 2.67M 100.15M
Capital lease obligations 2.79M 3.65M 2.88M 1.62M -
Long term debt total - - - 13.13M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.57600M -2.42800M 0.00000M -
Change to liabilities 0.41M 3.70M 0.16M 0.54M
Total cashflows from investing activities -0.57600M -2.42800M 0.20M -2.42800M
Net borrowings 0.07M - - 1.50M
Total cash from financing activities 0.06M 100.97M 11.29M 29.13M
Change to operating activities 2.17M -1.91700M 0.94M 1.39M
Net income -37.68500M -30.63700M -31.66900M -4.98700M
Change in cash -46.37900M 64.86M -6.98000M 27.16M
Begin period cash flow 85.05M 20.18M 27.16M -
End period cash flow 38.67M 85.05M 20.18M 27.16M
Total cash from operating activities -45.85800M -33.67800M -18.26700M -1.96900M
Issuance of capital stock 0.00000M 10.75M 11.23M -
Depreciation 0.97M 0.38M 0.38M 0.38M
Other cashflows from investing activities - - 0.20M -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables -0.66300M 0.60M 0.60M 0.60M
Sale purchase of stock 0.03M 5.70M - -
Other cashflows from financing activities -0.57600M 90.22M 0.20M 89.98M
Change to netincome -8.83400M 0.55M 5.89M 1.09M
Capital expenditures 0.58M 2.43M 2.43M 2.43M
Change receivables -0.66300M 0.60M - -
Cash flows other operating -0.05600M -8.26300M -0.20837M -
Exchange rate changes - - - -
Cash and cash equivalents changes -46.37900M 64.86M -0.44264M -
Change in working capital -0.64900M 1.62M 1.30M -
Stock based compensation 4.09M 1.05M 1.21M -
Other non cash items -12.59000M -9.08800M 10.90M -
Free cash flow -46.43400M -36.10600M -18.26700M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
JSPR
Jasper Therapeutics Inc		 0.06 4.58% 1.37 - - - 5.34 -4.9396
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Jasper Therapeutics Inc

2200 Bridge Pkwy, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Chair of Scientific Advisory Board & Director 1957
Mr. Jeetinder Singh Mahal M.B.A. CFO, COO & Corp. Sec. 1973
Dr. Kevin N. Heller M.D. Exec. VP of R&D 1971
Mr. Ronald A. Martell Pres, CEO & Director 1962
Dr. Susan Prohaska Ph.D. Co-Founder and VP of Operations & Program Management NA
Dr. Carol Zoltowski Sr. VP of Regulatory Affairs & Quality 1950
Dr. Wendy Pang M.D., Ph.D. Sr. VP of Research & Translational Medicine NA
Mr. Ronald A. Martell President, CEO & Director 1962
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Chair of Scientific Advisory Board & Director 1956
Mr. Jeetinder Singh Mahal M.B.A. Chief Operating Officer 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.